| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.7.5.509 |
| P698 | PubMed publication ID | 16553567 |
| P2093 | author name string | Rajinder Singh | |
| Jason John | |||
| Manit Arya | |||
| Hitendra R H Patel | |||
| Arun Sahai | |||
| Mohammed Shamim Khan | |||
| P2860 | cites work | How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study | Q28202479 |
| Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo | Q28379545 | ||
| Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder | Q33539501 | ||
| The activation of bladder wall afferent nerves | Q33542438 | ||
| Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. | Q34543969 | ||
| Enterocystoplasty | Q34559851 | ||
| Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review | Q34950386 | ||
| Pharmacologic perspective on the physiology of the lower urinary tract | Q35031200 | ||
| Urinary incontinence: newer pharmacotherapeutic trends | Q35539138 | ||
| Management of overactive bladder | Q35671074 | ||
| The autonomous bladder: a view of the origin of bladder overactivity and sensory urge | Q35685704 | ||
| Pharmacologic therapy of lower urinary tract dysfunction. | Q35692493 | ||
| Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder | Q35710439 | ||
| Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence | Q35938505 | ||
| The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis | Q36122988 | ||
| Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data | Q36856528 | ||
| Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity | Q39407286 | ||
| A neurologic basis for the overactive bladder | Q41679682 | ||
| A myogenic basis for the overactive bladder | Q41679687 | ||
| Efficacy of bladder training in older women with urinary incontinence | Q41824956 | ||
| Distribution of afferent axons in the bladder of rats | Q42482443 | ||
| Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? | Q42631219 | ||
| Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome | Q42648179 | ||
| Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder | Q42660202 | ||
| Overactive bladder: a clinical entity or a marketing hype? | Q42699336 | ||
| Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial | Q43310817 | ||
| Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. | Q43542367 | ||
| A quantitative analysis of purinoceptor expression in human fetal and adult bladders | Q43601082 | ||
| Tolterodine: a safe and effective treatment for older patients with overactive bladder | Q43674684 | ||
| Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder | Q43715524 | ||
| Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study | Q43981420 | ||
| Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients | Q44004623 | ||
| Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder | Q44013297 | ||
| Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder | Q44035116 | ||
| The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro | Q44068017 | ||
| Mechanisms underlying the recovery of urinary bladder function following spinal cord injury | Q44159727 | ||
| Autonomous activity in the isolated guinea pig bladder | Q44276818 | ||
| Oxybutynin in bladder spasm, neurogenic bladder, and enuresis | Q44315476 | ||
| Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence | Q44534042 | ||
| Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial | Q44559884 | ||
| Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects | Q44559886 | ||
| Clinical efficacy and tolerability of extended‐release tolterodine and immediate‐release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo‐controlled trial | Q44655032 | ||
| Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells | Q44683028 | ||
| Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity | Q44721051 | ||
| Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder | Q44756641 | ||
| Signal transduction underlying carbachol-induced contraction of human urinary bladder | Q44760506 | ||
| In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. | Q44922103 | ||
| Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience | Q45001317 | ||
| Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial | Q45012360 | ||
| Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial | Q45083861 | ||
| Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder | Q45148608 | ||
| Improved quality of life in patients with overactive bladder symptoms treated with solifenacin | Q45215936 | ||
| Intravesical oxybutynin chloride: experience with 42 patients | Q46111859 | ||
| A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder | Q46445206 | ||
| Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow | Q46528879 | ||
| Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder | Q46535726 | ||
| Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients | Q46538992 | ||
| Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. | Q46557454 | ||
| Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist | Q46577108 | ||
| Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis | Q46591360 | ||
| Estimated economic costs of overactive bladder in the United States | Q46914426 | ||
| A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. | Q51839265 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. | Q53342637 | ||
| Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. | Q53958530 | ||
| Behavioral vs Drug Treatment for Urge Urinary Incontinence in Older Women | Q56639150 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacotherapy | Q701216 |
| P304 | page(s) | 509-527 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy | |
| P478 | volume | 7 |
Search more.